Breath Analysis for the Detection of Invasive Fungal Infections

Launched by UNIVERSITY OF ZURICH · Aug 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to detect invasive fungal infections (IFI) in patients with leukemia who are undergoing chemotherapy. These patients often have low levels of white blood cells, which makes them more vulnerable to infections. The current methods to diagnose these infections can be risky and not very accurate. In this trial, researchers are trying to find specific substances in patients' breath that can indicate the presence of these fungal infections, using a specialized technique called mass spectrometry.

To join this study, participants must be diagnosed with acute leukemia and plan to undergo chemotherapy that will keep them in the hospital for at least two weeks. They should also be experiencing a low white blood cell count. Patients who have difficulty following instructions for the breath analysis or have certain physical conditions that make it hard to use a mouthpiece may not be eligible. Those who participate can expect to provide breath samples, which could help improve the way doctors diagnose these serious infections in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of acute leukemia
• • Planned chemotherapy with a duration of hospitalisation of 2 weeks or longer
• • Neutropenia (\<500/µl) present at inclusion or planned chemotherapy with expected neutropenia (\<500/µl) for more than 7 days
• Exclusion Criteria:
• • Unable to follow instructions for breath analysis
• • Anatomic abnormalities precluding the use of a mouthpiece for breath analysis